COMPANY PROFILE

Link Cell Therapies

Explore full profile

A True CAR T Cell AND-Gate

South San Francisco, United StatesFounded 2022Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Link Cell Therapies

Link Cell Therapies is a biotechnology company focused on developing next-generation adoptive cell therapies aimed at treating cancer patients. The company operates in the healthcare and life sciences market, primarily serving patients in need of advanced cancer treatments. Link Cell Therapies leverages its proprietary platforms to create precise and effective cell therapies, which are designed to target specific cancer cells with high accuracy. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic products. Revenue is generated through partnerships, grants, and future sales of approved therapies. The company is led by a team of experienced scientists and industry professionals, including Bryan Smith, Ph.D., who leads target discovery efforts. Link Cell Therapies aims to bring innovative and effective treatments to the clinic, improving patient outcomes and advancing the field of oncology.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: South San Francisco, United States
Employees: 27
Open positions: 2
Dealroom signal: 55.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Immune System, Gene Therapy, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Dec 2025	$60M	$240M	Sheatree Capital · Johnson & Johnson Innovation · Wing Venture Capital · Kyowa Kirin	↗
SPINOUTOther financing	Jan 2022	$0	—	Stanford University	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Link Cell Therapies website traffic

Latest recorded traffic for Link Cell Therapies is 2.4K monthly website visits, down 4% over the last three months. Link Cell Therapies's team grew 237.5% over the past year.

Latest monthly visits2.4K 3-month web change-4% 1-year team growth+237.5%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior/Principal Scientist, Pipeline DevelopmentSouth San Francisco, CA · Other · Jul 19, 2026 Scientist I – Molecular Biology and Cell Line Engineering Lead, Cell TherapySouth San Francisco, CA · Other · Feb 24, 2026 Scientist (I/II), In Vivo PharmacologySan Francisco, California, United States · Other · Jan 16, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ITImmunos TherapeuticsDeveloping the next generation of novel immunotherapies that will improve the lives of patients with serious diseases	Zurich, Switzerland	Operational	11	$88M	$325M
IMImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system	Uppsala kommun, Sweden	Acquired
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
HTHiFiBiO TherapeuticsAn emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases	Cambridge, United States	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
GTGalecto \| Damora TherapeuticsBiotechnology for mutant calreticulin-driven hematologic disorders, formerly known as Galecto	Copenhagen, Denmark	Operational
SCScancellClinical-stage immunotherapies for difficult-to-treat cancers	Oxford, United Kingdom	Operational
INInspirnaBiotechnology company developing drugs for the treatment of cancer	New York City, United States	Operational